Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
about
Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.Biomarker assessment and molecular testing for prognostication in breast cancer.The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.Estimating the OncotypeDX score: validation of an inexpensive estimation tool.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.The Relationship of Race, Oncotype DX, and Ki67 in a Population Highly Screened For Breast Cancer.Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).The value of algorithms predicting the Oncotype DX recurrence score should not be underestimated!Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
P2860
Q27853207-5B682ACB-BE28-447C-AFD7-7C3C747B3DADQ31153510-2A95A83B-3EDA-4CAB-BF50-23F15B5A801CQ31167768-09792C22-69AD-4EE1-B8B9-54F746E0DE6AQ33756398-38948A81-8D8A-4F49-AF01-27600586AFC7Q33915010-6F7E35E6-3129-4D2F-831F-1EA6377B87ACQ38696790-4E2C36FA-6F8E-4AF1-A94F-EA982A2C22FDQ38747402-5A159AF4-338F-4E49-83A6-A1975B8E1907Q38761797-AAA3E1FB-953A-4C79-88AB-B4469C023A50Q39121120-AA905613-17EC-4F9E-BCC7-429C6CF3F6CDQ39187437-CA8FA1D2-224C-458B-843E-6DF41EF5AB13Q46162590-A924FC0C-800E-43CB-A397-687BF6A183B9Q46383705-B7D3E9DE-E210-45FC-837F-20114BE8C092Q47205521-4CCCE8F0-35D7-49F8-9EB8-0CDE5BF370EAQ47869675-BF772458-BB6F-43A4-9AD2-49148458C526Q47887164-3DE4558F-9FFA-4C58-83AA-AAFCD5FAA471Q51827185-B6EAD2E8-D54A-4B86-B55C-BEEDD4CC4D53Q55182367-346A6B73-5965-4A3C-B8B8-BAAA3CE196A3
P2860
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Use of modified Magee equation ...... Oncotype DX recurrence score.
@en
Use of modified Magee equation ...... Oncotype DX recurrence score.
@nl
type
label
Use of modified Magee equation ...... Oncotype DX recurrence score.
@en
Use of modified Magee equation ...... Oncotype DX recurrence score.
@nl
prefLabel
Use of modified Magee equation ...... Oncotype DX recurrence score.
@en
Use of modified Magee equation ...... Oncotype DX recurrence score.
@nl
P2093
P2860
P1433
P1476
Use of modified Magee equation ...... Oncotype DX recurrence score.
@en
P2093
Alissa Huston
Bradley M Turner
David G Hicks
Kristin A Skinner
Marilyn Ling
Mary C Jackson
Michelle Shayne
Nyrie Soukiazian
P2860
P2888
P304
P356
10.1038/MODPATHOL.2015.50
P577
2015-05-01T00:00:00Z
P5875
P6179
1038476233